NIELL-2002-INTERGROUP

Regimen

Experimental
Paclitaxel 175 mg/m2 + etoposide 80 mg/m2 d1-3 + cisplatin 80 mg/m2 + G-CSF (PET) x6 cycles
Control
Cisplatin 80 mg/m2 + etoposide 80 mg/m2 d1-3 (EP) x6 cycles q3w

Population

Untreated extensive-stage small-cell lung cancer

Key finding

mOS 10.6 mo (PET) vs 9.9 mo (EP), P=0.169 (NS); median failure-free survival 6 vs 5.9 mo (P=0.179); toxic deaths 6.5% vs 2.4%; PET did not improve outcomes

Source: PMID 15923572

Timeline

    Guideline citations

    • NCCN SCLC (p.25)